Substituted dihydrophenanthridinesulfonamides

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C546S108000, C546S109000, C546S110000, C544S324000, C514S269000

Reexamination Certificate

active

06894061

ABSTRACT:
This invention provides a compound of formulae (I) or (II) having the structureor a pharmaceutically acceptable salt thereof which are useful for the treatment of the inflammatory component of diseases and are particularly useful in treating atherosclerosis, myocardial infarction, congestive heart failure, inflammatory bowel disease, arthritis, type II diabetes, and autoimmune diseases such as multiple sclerosis and rheumatiod arthritis.

REFERENCES:
patent: 5153185 (1992-10-01), DiNinno et al.
patent: 509756 (1992-10-01), None
patent: 509780 (1992-10-01), None
patent: 761669 A2 (1997-03-01), None
patent: 5762 (1968-02-01), None
patent: 1 135 947 (1968-12-01), None
patent: 9905113 (1999-02-01), None
patent: 0042018 (2000-07-01), None
patent: 0042020 (2000-07-01), None
patent: 0142219 (2001-06-01), None
patent: 0205616 (2002-01-01), None
patent: 0220463 (2002-03-01), None
Adams, M. R. et al., “Inhibition of Coronary Artery Atherosclerosis by 17-beta Estradiol in Ovariectomized Monkeys,”Arterio.,1990, 10(6), 1051-1057.
Alexander et. al., “Initiation of Hormone Replacement Therapy After Acute Myocardial Infarction Is Associated With More Cardiac Events During Follow-Up,”J. Am. Coll. Cardio.,2001, 38, 1-7.
Bauer M. A., Herrmann F., “Interleukin-6 in clinical medicine,”Ann. Hematol.,1991, 62, 203-210.
Cefalu, W., “The Use of Hormone Replacement Therapy in Postmenopausal Women with Type 2 Diabetes,”J Womens Health&Gender-based Med.,2001, 10(3), 241-255.
Chin-Chi Lin et.al., “Pulmonary function changes and increased Th-2 cytokine expression and nuclear factor kB activation in the lung after sensitization and allergen challenge in brown Norway rats,”Immunol. Lett.,2000, 73, 57-64.
Delyani, J. A. et al., “Protection from Myocardial Reperfusion Injury by Acute Administration of 17β-Estradiol,”J. Molec. Cell. Cardiol.,1996, 28, 1001-1008.
Felson, D. T. et al., “The effects of estrogen on osteoarthritis,”,Curr Opinion Rheum,1998, 10, 269-272.
Finkelstein, J. et al. “Derivatives of 6-Methyl-5,6-dihydrophenanthridine,”J. Am. Chem. Soc.,1950, 72, 3282-3.
Grigg, R. et al., “Palladium Catalysed Triscyclisation-Anion Capture Queuing Cascades,”Tetrahedron Lett.,1997, 38(10), 1825-1828.
Grigg, R. et al., “Phenanthrene type heterocycles via Rh(I) catalysed [2+2+2]-cycloaddition and Pd(0) catalysed arylation,”Tetrahedron Lett.,2000, 41(16), 3003-3006.
Grigg, R. et al., “Palladium Catalysed Intramolecular Coupling of Aryl and Benzylic Halides and Related Tandem Cyclisations,”Tetrahedron Lett.,1991, 32(31), 3859-3862.
Grodstein, F. et. al., “A Prospective, Observational Study of Postmenopausal Hormone Therapy and Primary Prevention of Cardiovascular Disease,”Ann. Int. Med.,2000, 133, 933-41.
Grodstein F. et. al., “Postmenopausal Hormone Use and Secondary Prevention of Coronary Events in the Nurses' Health Study,”Ann. Int. Med,2001, 135, 1-8.
Hulley, S. et. al., “Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women,”J. Am. Med. Assoc.,1998, 280, 605-13.
Huppatz, J. L. et al., “Pschorr Reactions With Sulphonamides Derived From N-Benzyl-o-Phenylenediamine: A New Route to Phenanthridine, and a New Type of Molecular Rearrangement,”Aust. J. Chem.,1963, 16, 417-431.
Huppatz, J. L. et al., “Synthesis of 9-Bromophenanthridine and 7-Bromophenanthridine by Pschorr Reactions with Sulphonamides Derived from N-p-Bromobenzyl- and N-o-Bromobenzyl-o-Phenylenediamines, and a New Route to N-Sulphonylcarbazoles,”Aust. J. Chem.,1964, 17, 1407-1417.
Huppatz, J. L. et al., “Pschorr Reactions with Sulphonamides Derived from N-Aminobenzyl-Aniline: Synthesis of a 4-Bromophenanthridine and Formation of 6-Phenyl-7H-Dibenzo[d,f]-[1,2]-Thiazepine-5-Dioxide,”Aust. J. Chem.,1965, 18(2), 206-212.
Kant, J. et al., “Reissert Compound Studies. XLV. The Phenanthridine Reissert Compound,”J. Heterocycl. Chem.,Mar.-Apr. 1984, 21, 425-427.
Kurebayashi S. et. al., “Characterization of Mechanisms of Interleukin-6 Gene Repression by Estrogen Receptor,”J. Steroid Biochem. Molec. Biol.,1997, 60, 11-17.
Miura, M. et al., “Oxidative Cross-Coupling of N-(2′-Phenylphenyl)benzene-sulfonamides or Benzoic and Naphthoic Acids with Alkenes Using a Palladium-Copper Catalyst System under Air,”J. Org. Chem.,1998, 63, (15), 5211-5215.
Nathan, L. et. al., “Estradiol Inhibits Leukocyte Adhesion and Transendothelial Migration in Rabits In Vivo,”Circ. Res.,1999, 85, 377-385.
Paterson et al., “Azabenzocycloheptenones. Part IV. An Azadibenzotropone,”J. Chem. Soc.,1962, 3468-3472.
Patra, P. K., et al., “A New Regiospecific Method for the Synthesis of Substituted Phenanthridines and Benzo[j]phenanthridines via Aromatic Annelation of 1-N-Benzenesulfonyl-3-[Bis9methylthio)methylene]-1,2,3,4-tetrahydroquinoline-4-one,”Tetrahedron,1998, 54(34), 10167-10178.
Peaston, W. C. et al, “Azabenzocycloheptenones. VIII. Further observations in the dibenz[b,d]azepine-7-one field,”J. Chem. Soc.,1968, 19, 2481-4. Chemical Abstracts Service, HCAPLUS Accession No. 1968:496433, Document No. 69:96433 (Abstract).
Pelletier et al., “Osteoarthritis, an Inflammatory Disease,”Arthr.&Rheum.,2001, 44:1237-1247.
Reis et. al., “Estrogen Is Associated With Improved Survival in Aging Women With Congestive Heart Failure: Analysis of the Vesnarinone Studies,”J. Am. Coll. Cardio.,2000, 36, 529-33.
Roth, A. et. al., “Phytoestrogen Kaempferol (3,4,5,7-Tetrahydroxylflavone) Protects PC12 and T47D Cells From β-Amyloid-Induced Toxicity,”J. Neurosci. Res.,1999, 57, 399-404.
Schonknecht, P. et. al., “Reduced cerebrospinal fluid estradiol levels are associated with increased β-amyloid levels in female patients with Alzheimer's disease,”Neurosci. Lett.,2001, 307, 122-124.
Sullivan, T. R. et al. “Estrogen Inhibits the Response-to-Injury in a Mouse Carotid Artery Model,”J. Clin. Invst.,1995, 96, 2482-8.
Ulmer, L. et al., “Mono- and bisfunctionalization of fullerenes with N-containing reactants,”J. Inf. Rec.,1998, 24(3-4), 243-247. Chemical Abstracts Service, Accession No. 1999:251961, HCAPLUS Registry No. 226909-66-6 (Abstract).
Yuan et al., “Reversal of Obesity- and Diet-Induced Insulin Resistance with Salicylates or Targeted Disruption of Ikkβ,”Science,2001, 293, 1673-7.
Chemical Abstracts Service, CA Registry No. 213486-09-0.
Chemical Abstracts Service, CA Registry No. 213486-08-9.
Chemical Abstracts Service, CA Registry No. 211621-30-6.
Chemical Abstracts Service, CA Registry No. 211621-27-1.
Chemical Abstracts Service, CA Registry No. 211621-26-0.
Chemical Abstracts Service, CA Registry No. 211621-25-9.
Chemical Abstracts Service, CA Registry No. 211621-24-8.
Chemical Abstracts Service, CA Registry No. 211621-23-7.
Chemical Abstracts Service, CA Registry No. 211621-22-6.
Chemical Abstracts Service, CA Registry No. 211621-21-5.
Chemical Abstracts Service, CA Registry No. 211621-20-4.
Chemical Abstracts Service, CA Registry No. 91871-03-3.
Chemical Abstracts Service, CA Registry No. 19711-96-7.
Chemical Abstracts Service, CA Registry No. 2608-29-9.
Chemical Abstracts Service, CA Registry No. 1096-83-9.
Chemical Abstracts Service, CA Registry No. 279680-75-0.
Chemical Abstracts Service, CA Registry No. 279680-74-9.
Chemical Abstracts Service, CA Registry No. 226909-66-6.
Chemical Abstracts Service, CA Registry No. 226909-63-3.
Chemical Abstracts Service, CA Registry No. 213486-15-8.
Chemical Abstracts Service, CA Registry No. 213486-14-7.
Chemical Abstracts Service, CA Registry No. 213486-13-6.
Chemical Abstracts Service, CA Registry No. 213486-12-5.
Chemical Abstracts Service, CA Registry No. 213486-11-4.
Chemical Abstracts Service, CA Registry No. 213486-10-3.
Chemical Abstrac

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Substituted dihydrophenanthridinesulfonamides does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Substituted dihydrophenanthridinesulfonamides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted dihydrophenanthridinesulfonamides will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3432406

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.